Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib for advanced nasopharyngeal carcinoma (second-line, single-arm)
ChiCTR2100041619Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in nasopharyngeal carcinoma (NPC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival (PFS). Started Jan 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100041619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041619.